Seres Therapeutics Stock Price Target

That means the average analyst price target for mcrb stock is $20.57. In terms of price targets and.

Seres Therapeutics Up By 390 In A Day This Analyst Sees More Upside In The Cards

Based on mcrb analyst price targets, mcrb stock forecast is $20.57 (for a year from now).

Seres therapeutics stock price target. Mcrb) climbed more than 21% on tuesday. Seres therapeutics's share price could stay at $20.83 by jul 23, 2022. On average, they anticipate seres therapeutics' stock price to reach $20.83 in the next twelve months.

Mcrb analyst rating is buy. Mcrb) was reported by canaccord genuity on july 23, 2021. The prediction is based on 9 analyst estimates.

The company’s stock price has collected 5.75% of gains in the last five trading sessions. Shares of seres therapeutics ( nasdaq:mcrb) were soaring 17.1% higher as of 3:09 p.m. Shares of seres therapeutics (nasdaq:

Price target in 14 days: On the other hand, seres therapeutics' target price is what analysts think the stock is worth or could sell for in the future. When a stock reaches the.

Investors need to pay close attention to seres therapeutics (mcrb) stock based on the movements in the options market lately. Shares of seres therapeutics (nasdaq: The latest price target for seres therapeutics ( nasdaq:

Down from us$21.14, the current price target is an average from 8 analysts. The biotech stock, which closed at $8.82 on monday, opened at $8.63 on. In a report released yesterday, canaccord genuity also maintained a buy rating on the stock with a $42.00 price target.

The analyst firm set a price target for 29.00 expecting mcrb to rise to within 12. Press release reported on 08/05/21 that seres therapeutics to present at canaccord genuity 41st annual growth conference. The big gain came after the company announced that it has achieved its target.

This suggests a possible upside of 117.2% from the stock's current price. Stock is down 69% over the past year. The average seres therapeutics stock price prediction forecasts a potential downside of n/a from the current mcrb share price of $9.17.

The biotech stock, which closed at $8.82 on monday, opened at $8.63 on. Their forecasts range from $7.00 to $32.00. In recent trading, shares of seres therapeutics inc (symbol:

Seres therapeutics inc's number of analysts covering the stock is greater than 80.1% of pharmaceutical products stocks. The company is forecast to post a net loss per share of us$0.71 next year compared to a net loss per share of us$1.12 last year. The current price of seres therapeutics is the price at which seres therapeutics is currently trading.

*the average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Seres therapeutics stock forecast, mcrb stock price prediction. Looking to buy seres therapeutics stock?

Get the stock price and latest news for mcrb and start trading today with zero commissions. According to the issued ratings of 7 analysts in the last year, the consensus rating for seres therapeutics stock is buy based on the current 1 sell rating, 1 hold rating and 5 buy ratings for mcrb. New target price is 99% above last closing price of us$9.59.

On average, wall street analysts predict that. Seres therapeutics has an analyst consensus of moderate buy, with a price target consensus of $37.80, which is a 68.0% upside from current levels. The biotech stock, which closed at $8.82 on monday, opened at $8.63 on tuesday, then took off, climbing to a daily high.

Earnings data q2 2021 12am gmt. List of events that could affect this stock. The low price target for mcrb is $7.00, while the high price target is $32.00.

Is it worth investing in seres therapeutics inc. Mcrb has a higher average analyst price target than 25.04% of stocks in the mid market cap category. Seres therapeutics inc's variance in analysts' estimates is lower than 12.93% of stocks in the mid market cap category.

Seres therapeutics target price projection seres therapeutics' current and average target prices are 8.67 and 22.83, respectively. Mcrb) climbed more than 21% on tuesday. Press release reported on 10/13/21 that invaio sciences secures $50 million d

Seres therapeutics started at outperform with $19 stock price target at oppenheimer